Denosumab Discontinuation Rate in Patients Who Presented with Osteoporotic Vertebral Fracture During Pandemic.

This article examines the discontinuation of denosumab treatment for osteoporotic fractures during the COVID-19 pandemic. The study found that patients discontinued denosumab due to fear of limited access to hospitals and mobility restrictions. The discontinuation of denosumab without concomitant bisphosphonate use can increase the risk of bone loss and fractures. The study suggests that patients should be informed about the durability of denosumab treatment and temporarily switched to oral bisphosphonate therapy if necessary. However, the study has limitations, including a limited time period and a retrospective design. [Extracted from the article]